Novo Nordisk fellowships

Oxford University is currently recruiting four Postdoctoral Research Fellows and one Clinical Research Training Fellows as part of the Novo Nordisk Fellowship Program at the University of Oxford.

Novo Nordisk fellowship program

Applications are invited from basic scientists and clinicians wishing to undertake research with a focus on diabetes, cardiometabolism, liver and renal disease. Each fellowship is fully funded for three years. These prestigious fellowships are open to outstanding candidates of any nationality.

Please note that applicants for the Postdoctoral Research Fellowships must be no more than three years post PhD at the start of the fellowship (Autumn 2020). Please note that while we will consider all applications, the funding provided for the Clinical Research Training Fellowship will only cover home/EU DPhil fees.

See the overview of the eight projects below. 

Further information on the projects, the fellowship program and details on how to apply can be found at: www.rdm.ox.ac.uk/novo-nordisk-fellowships

Enquiries should be directed to:nn.fellowships@rdm.ox.ac.uk

The closing date for receipt of applications is: Midday on Wednesday 25 March 2020

Projects and principal investigators

Measuring molecules for medicine: quantifying human cardiac metabolic inflexibility in diabetic cardiomyopathy using in vivo Magnetic Resonance

Crosstalk between lesional and resident vascular macrophages in atherosclerosis

Hypoxia-Inducible Factor : a unifying mechanism underpinning multiple diabetes complications

Leveraging genomic approaches and genetic associations to identify potential new drug targets in cardiometabolic disease

Patient-specific bioinformatics linking coronary microvascular structure, function and gene expression

Uncovering the mechanism of action for the coronary artery disease GWAS gene JCAD

An integrative cross-omics study of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

The cellular pathology of early kidney disease

Notes

* Supervisor from the Novo Nordisk Research Centre Oxford.